Acetylation Process Control for X-ray Contrast Agent Purity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The existing acetylation processes for producing 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound A) result in high levels of by-products, leading to lower purity and yield, which is a challenge for industrial-scale production of non-ionic X-ray contrast agents.

Innovation Solution

Reducing the reaction temperature during the acetylation of Compound B by carefully adding a catalytic amount of an acid catalyst, such as para-toluene sulfonic acid, over a period of several hours, maintains the reaction temperature between 65-85 °C, significantly reducing by-product formation and improving the purity and yield of Compound A.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional acetylation process is used with high temperature, then reaction rate is improved, but by-product formation increases leading to lower purity

Engineering Contradiction:
Improvereaction rateVSAvoidpurity of Compound A
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent changes the temperature parameter from conventional high temperature to a controlled range of 65-85°C, and modifies the catalyst addition method from single-dose to gradual addition over several hours. These parameter changes enable the reaction to proceed at acceptable rates while maintaining low by-product formation and high purity of Compound A.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If conventional acetylation process is used, then production speed is maintained, but yield of Compound A decreases due to by-product formation

Engineering Contradiction:
Improveproduction speedVSAvoidyield of Compound A
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent implements feedback control by monitoring the reaction temperature and adjusting the catalyst addition rate accordingly. The temperature is maintained within 65-85°C by controlling the addition speed of the acid catalyst, ensuring optimal yield while maintaining production efficiency.

Inventive Principle:
Principle #23Feedback

3Speed

If acid catalyst is added quickly, then reaction proceeds faster, but temperature control becomes difficult leading to increased by-products

Engineering Contradiction:
Improvereaction speedVSAvoidtemperature control
Core Design Contradiction:
SpeedVSTemperature

Solution Approach 1:

The patent applies dynamic control by adjusting the catalyst addition rate based on real-time temperature conditions. Rather than adding the acid catalyst in a fixed manner, the addition is performed gradually over several hours with the rate adapted to maintain temperature within the optimal 65-85°C range, balancing reaction speed and temperature control.

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This alternative acetylation process achieves higher purity and yield of Compound A, enhancing the efficiency of the subsequent purification steps and reducing the overall cost of production on both laboratory and industrial scales.

Implementation Method 1

adding an acid catalyst (preferably, para-toluene sulfonic acid (PTSA)) to said slurry at a rate such that the reaction temperature is maintained at a temperature range of 65-85 °C

Methodology Applied
Scientific EffectCatalysis: Catalysis

Data Source

PatentEP3077366B1Alternative acetylation process in the synthesis of non-ionic xray contrast agents
Publication Date: 2017.08.09 GE HEALTHCARE AS
  • EP3077366B1 patent drawing
  • EP3077366B1 patent drawing
  • EP3077366B1 patent drawing

AI summary

An alternative acetylation process for the synthesis of 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide ("Compound A"), an intermediate in the industrial preparation of non-ionic X-ray contrast agents, is described. The process can be performed on an industrial scale to produce Compound A with improved purity and improved yields compared to the established processes.